Is interleukin-6 receptor blockade the holy grail for inflammatory diseases?

M. A. Febbraio, Stefan Rose-John, Bente Klarlund Pedersen

Research output: Contribution to journalComment / DebateOtherpeer-review

49 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) has been linked to a myriad of diseases associated with inflammation, including rheumatoid arthritis (RA), Crohns disease, and several types of cancer. In 2009 the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA. Although this treatment will certainly help in managing inflammatory disorders such as RA, we suggest that side effects of such blockade may be excess weight gain and hyperlipidemia.

Original languageEnglish
Pages (from-to)396-398
Number of pages3
JournalClinical Pharmacology & Therapeutics
Volume87
Issue number4
DOIs
Publication statusPublished - Apr 2010
Externally publishedYes

Cite this